About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
The Role of Inflammation in Myeloproliferative Neoplasms
By
Angela Fleischman
6 Videos
313 views
November 28, 2017
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:47
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations in R/R CLL - A Patient Case Study
Feat.
J. N. Allan
Featured Video
24:55
Treatment Considerations in CLL: Challenging Patient Cases
Treatment Considerations in Front-line CLL
Feat.
A. Zelenetz
Related Content
AUTOPLAY
ON
19:49
Rush University Medical Center
COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…
Feat.
S. Jain
18:41
CHEST 2022 Coverage
Role of Anticoagulants and Antiplatelet Agents for Patients With COV…
Feat.
V. Balasubramanian
21:20
Cleveland Clinic Rheumatology
How do I Recognize and Treat the VEXAS Syndrome?
Feat.
P. Grayson
31:18
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023
Thrombosis and Anticoagulation: 2023 Update
Feat.
S. Moll
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
28:10
Indy Hematology Review
Current Review of Benign Hematology and Coagulopathy
Feat.
C. Kessler
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
12:07
Douglas Tremblay
Monitoring Patients With MF: When to Switch Treatment
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
13:36
Vanderbilt University Medical Center (VUMC)
Venous Thromboembolism Prophylaxis in Newly Diagnosed MM
Feat.
M. Baljevic
09:46
Scripps MD Anderson Cancer Center
Ruxolitinib in Polycythemia Vera: Learnings From the RESPONSE Trial
Feat.
D. Hermel
12:18
Fred Hutchinson Cancer Center
Management of MPNs for the Community Oncologist
Feat.
H. Deeg
08:44
Krisstina Gowin
Management of Aquagenic Pruritis in Polycythemia Vera